BRAF and melanoma: Cesi et al. found that an increase in ROS production led to inhibition of pyruvate dehydrogenase (PDH) in response to BRAF inhibitor treatment in BRAF V600E mutated, but not wild type BRAF or NRAS mutated melanoma cells.